KLAR Partners acquires BÜHLMANN Laboratories AG from its founder to build a leading specialty in-vitro diagnostics company.

Funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) acquire from its founder BÜHLMANN Laboratories AG (“BÜHLMANN” or the “Company”), a leading provider of specialty in-vitro diagnostic (IVD) tests and instruments headquartered in Basel, Switzerland.

Since its founding nearly half a century ago, under the leadership of its founder Dr Roland P. Bühlmann the Company has been at the forefront of developing innovative diagnostic tests and instruments used to diagnose gastrointestinal inflammation, autoimmunity and allergy. As we welcome BÜHLMANN into the KLAR family, we honour Dr. Bühlmann’s legacy and look forward to support the Company's continued growth.

“If I were 20 years younger, I would not have sold my company”, noted Dr. Bühlmann, “but today, it is my responsibility as an entrepreneur to secure the future of BÜHLMANN. I am very pleased that we have found professional, motivated and committed new owners in KLAR.”

“We are grateful to Dr. Bühlmann for the trust and opportunity to acquire such an outstanding in-vitro diagnostics company and one of the global brands in the industry. BÜHLMANN stands for innovative, high quality products and customer-focused services. KLAR will continue to invest in BÜHLMANN and in the Schönenbuch site. Our goal is to help the Company achieve its full potential as a global specialty IVD leader”, commented Ahmet Mesinoglu of KLAR Partners.

As part of the founder transition, Donal Quinn, a KLAR senior advisor and former CEO of Siemens Diagnostics, has been appointed as Chairman of the Company’s Advisory Board; Laurent Collignon, the Company’s current Chief Business Development Officer, has been appointed as CEO, replacing the current CEO Dr. Thomas Hafen, who will continue to serve BÜHLMANN as a senior advisor after he retires from active duties in September 2024.

Further Information:

Ahmet Mesinoglu
am@klarpartners.com
+32 470 827 433

Carl Johan Falkenberg
cj@klarpartners.com
+46 733 699 579

About BÜHLMANN

BÜHLMANN is a mid-sized Swiss company, located in Schönenbuch, near Basel. Since 1976, the purpose of the company is to develop and market specialty, high-quality in-vitro diagnostics and to distribute third-party molecular diagnostics products. The company promotes its own products through its own affiliates as well as through more than 60 qualified distributors worldwide. BÜHLMANN's priorities are to offer quality and specialty in-vitro diagnostics to its customers and to provide a stable and motivating work environment to its employees.

About KLAR:

KLAR Partners is a European private equity firm focused on investments in companies operating in business services and industrial technology. The companies in which KLAR invests each have an annual turnover of approximately EUR 50-500m and are headquartered in the DACH, Nordics and Benelux regions. With investment professionals located in London, Stockholm, Frankfurt, and Brussels, together with a broad international network in the industry, KLAR has a proven business model to support, develop and grow companies. KLAR's senior professionals have worked together for many years and have more than 50 years of combined investment experience in KLAR's industry-specific and geographical focus area. KLAR Partners is a signatory of United Nations Principles for Responsible Investment.

Published June 5, 2024
Privacy NoticeTerms of UseSFDRCookie Settings